An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy
Status:
NOT_YET_RECRUITING
Trial end date:
2029-05-17
Target enrollment:
Participant gender:
Summary
The primary objective of the trial is to describe the long-term safety and tolerability of TEV-56286 administered orally for the treatment of adult participants with Multiple System Atrophy (MSA).
A secondary objective of the trial is to further describe the safety and tolerability of TEV-56286.
The planned total duration of the trial is approximately 100 weeks.